Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.69 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.69 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.69 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.69 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12082104 | 0.91 | OPRM1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL12769902 | 0.90 | OPRD1 (0.62) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL15249248 | 0.90 | OPRD1 (0.74) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL678993 | 0.90 | OPRD1 (0.74) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL29359245 | 0.90 | OPRD1 (0.74) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Hydrochloric Acid SCHEMBL31058090 | 0.89 | OPRD1 (0.73) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Propionic Acid SCHEMBL28993771 | 0.89 | OPRD1 (0.67) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL6755526 | 0.88 | OPRD1 (0.79) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL2582986 | 0.88 | OPRD1 (0.66) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL6459794 | 0.87 | OPRD1 (0.77) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6737518-B1 | REACTING 4,5-EPOXYMORPHINAN-6-OLS WITH BROMOGLUCURONIDES IN THE PRESENCE OF ZINC BROMIDE; DEPROTECTING END PRODUCTS TO MAKE MORPHINE-6-BETA-D-GLUCURONIDE (M6G) | CENES LIMITED (GB) | 2004-05-18 | — | — | US | claimed |
| US-20040053854-A1 | Process for preparation of 4,5-Epoxymorphinan-6-oxyglucuronides | CENES LIMITED (GB) | 2004-03-18 | — | — | US | claimed |
| EP-1053244-B1 | GLYCOSIDATION OF 4,5-EPOXYMORPHINAN-6-OLS | FINETECH LTD (IL) | 2003-10-22 | — | — | EP | claimed |
| US-6555665-B1 | With a thioglycoside as a glycoside donor in the presence of a thiophilic promoter; stereoselectivity, high yield; hydrolysing product to obtain Morphine-6-beta-D-glucuronide (M6G) | CENES LIMITED (GB) | 2003-04-29 | — | — | US | claimed |
| US-6737518-B1 | REACTING 4,5-EPOXYMORPHINAN-6-OLS WITH BROMOGLUCURONIDES IN THE PRESENCE OF ZINC BROMIDE; DEPROTECTING END PRODUCTS TO MAKE MORPHINE-6-BETA-D-GLUCURONIDE (M6G) | CENES LIMITED (GB) | 2004-05-18 | — | — | US | disclosed |
| US-20040053854-A1 | Process for preparation of 4,5-Epoxymorphinan-6-oxyglucuronides | CENES LIMITED (GB) | 2004-03-18 | — | — | US | disclosed |
| EP-1053244-B1 | GLYCOSIDATION OF 4,5-EPOXYMORPHINAN-6-OLS | FINETECH LTD (IL) | 2003-10-22 | — | — | EP | disclosed |
| US-6555665-B1 | With a thioglycoside as a glycoside donor in the presence of a thiophilic promoter; stereoselectivity, high yield; hydrolysing product to obtain Morphine-6-beta-D-glucuronide (M6G) | CENES LIMITED (GB) | 2003-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053854-A1 | Process for preparation of 4,5-Epoxymorphinan-6-oxyglucuronides | OGFR, OSTC, GALE | OPRD1 21/4885OPRM1 4/4885OPRK1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.